CGTX Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cognition Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.42 |
| 52 Week High | US$2.95 |
| 52 Week Low | US$0.34 |
| Beta | 1.25 |
| 11 Month Change | -15.19% |
| 3 Month Change | -25.61% |
| 1 Year Change | -74.46% |
| 33 Year Change | -94.73% |
| 5 Year Change | n/a |
| Change since IPO | -96.68% |
Recent News & Updates
Recent updates
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Sep 06
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Jul 31Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
May 22Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Apr 18Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Nov 30Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
Aug 15Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
Mar 17Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Sep 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Aug 12Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
Aug 05We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Mar 19Shareholder Returns
| CGTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.4% | 0.9% | 1.1% |
| 1Y | -74.5% | 14.0% | 32.4% |
Return vs Industry: CGTX underperformed the US Pharmaceuticals industry which returned 14% over the past year.
Return vs Market: CGTX underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| CGTX volatility | |
|---|---|
| CGTX Average Weekly Movement | 14.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CGTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CGTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 27 | Lisa Ricciardi | www.cogrx.com |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Cognition Therapeutics, Inc. Fundamentals Summary
| CGTX fundamental statistics | |
|---|---|
| Market cap | US$15.71m |
| Earnings (TTM) | -US$34.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs CGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$34.27m |
| Earnings | -US$34.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CGTX perform over the long term?
See historical performance and comparison